PMID- 22682747
OWN - NLM
STAT- MEDLINE
DCOM- 20121107
LR  - 20151119
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 104
IP  - 1
DP  - 2012 Jul
TI  - Circulating regulatory T cells of cancer patients receiving radiochemotherapy may 
      be useful to individualize cancer treatment.
PG  - 131-8
LID - 10.1016/j.radonc.2012.05.003 [doi]
AB  - BACKGROUND AND PURPOSE: Dendritic cells (DCs) and regulatory T cells (Treg) play 
      a major role in anti-tumor immune response of cancer patients. We investigated 
      the effect of radiochemotherapy on patients' blood immune cells and their 
      predictive value for tumor response. MATERIALS AND METHODS: DCs and Treg of 
      colorectal cancer (CRC) or breast cancer (BC) patients were examined through 
      multicolor flow cytometry before the beginning and after the first week of 
      radiochemotherapy (RCT). DCs were stained for BDCA1 and BDCA2, Treg were stained 
      for CD4, CD25, CD127 and FoxP3. IL-2, IL-10 and TNF-alpha plasma levels of CRC 
      patients were also determined. We examined the interrelationship between immune 
      cell count alterations, applied dose values, cytokine plasma levels as well as 
      histopathological parameters. RESULTS: DCs were increased in BC and CRC patients 
      compared to healthy control individuals (HC). CRC patients had higher levels of 
      Treg (59.0%) compared to BC patients (31.3%) and HC (27.0%). Treg of CRC (58.7% 
      vs. 41.3% p<0.001) but not BC patients (31.3% vs. 38.8%, p=0.164) decreased 
      distinctly after the first week of radiation therapy. Applied dose values and 
      decrease of Treg correlated positively (r=0.216, p=0.054). We also found a 
      positive correlation of IL-10 plasma levels and Treg levels (r=0.748, p=0.021). 
      CRC patients with favorable tumor stage (<ypT3a) have higher levels of Treg after 
      5 days of RCT (49.4% vs. 34.0%, p=0.043). CONCLUSION: Higher Treg levels are 
      associated with favorable tumor stage. We hypothesize that a dramatic decrease of 
      Treg after in vivo irradiation may be a good indicator for necessary dose 
      adjustments in radiation therapy of CRC patients.
CI  - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Schmidt, Manuel A
AU  - Schmidt MA
AD  - Department of Radiation Oncology, Friedrich-Alexander-University 
      Erlangen-Nurnberg, Universitatsstrasse 27, Erlangen, Germany.
FAU - Fortsch, Claudia
AU  - Fortsch C
FAU - Schmidt, Manfred
AU  - Schmidt M
FAU - Rau, Tilman T
AU  - Rau TT
FAU - Fietkau, Rainer
AU  - Fietkau R
FAU - Distel, Luitpold V
AU  - Distel LV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120609
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Cytokines)
SB  - IM
MH  - Breast Neoplasms/immunology
MH  - *Chemoradiotherapy
MH  - Colorectal Neoplasms/immunology
MH  - Cytokines/blood
MH  - Dendritic Cells/immunology
MH  - Humans
MH  - Neoplasms/immunology/*therapy
MH  - Precision Medicine
MH  - T-Lymphocytes, Regulatory/*immunology
EDAT- 2012/06/12 06:00
MHDA- 2012/11/08 06:00
CRDT- 2012/06/12 06:00
PHST- 2011/11/28 00:00 [received]
PHST- 2012/05/02 00:00 [revised]
PHST- 2012/05/14 00:00 [accepted]
PHST- 2012/06/12 06:00 [entrez]
PHST- 2012/06/12 06:00 [pubmed]
PHST- 2012/11/08 06:00 [medline]
AID - S0167-8140(12)00232-0 [pii]
AID - 10.1016/j.radonc.2012.05.003 [doi]
PST - ppublish
SO  - Radiother Oncol. 2012 Jul;104(1):131-8. doi: 10.1016/j.radonc.2012.05.003. Epub 
      2012 Jun 9.